Expression of serum macrophage migration inhibitory factor and Tau protein in patients with severe hypertensive intracerebral hemorrhage and their relationships with clinical outcome / 中风与神经疾病杂志

ABSTRACT

@#Objective To explore the expression levels of serum macrophage migration inhibitory factor(MIF) and Tau protein in patients with severe hypertensive intracerebral hemorrhage(HICH),and analyze the relationships between their levels and patient outcome,and to provide a reference for clinical treatment of such patients. Methods We included 120 patients with severe HICH and 50 age-and sex-matched healthy controls from health examination in Ziyang Hospital of West China Hospital of Sichuan University from January 2019 to November 2022.The MIF and Tau protein levels of the two groups were compared. After a follow-up of more than half a year,the patients were divided into poor-prognosis group and good-prognosis group according to the defined criteria to compare their levels of MIF and Tau protein. The receiver operating characteristic(ROC) curve and Kaplan-Meier method were used to explore the critical values of MIF and Tau protein levels for patients with poor prognosis and the relationships with the clinical outcome of severe HICH. Results The levels of serum MIF and Tau protein in the patients with severe HICH were significantly higher than those in the control group(P<0.05). The poor-prognosis group showed significantly higher levels of serum MIF and Tau protein than the good-prognosis group(P<0.05). The ROC curve showed that the cutoff points of serum MIF and Tau protein levels for predicting poor prognosis were 64.43 ng/L and 216.25 pg/ml,respectively. The area under the curve for using MIF to predict poor prognosis was 0.815(95%CI=0.759-0.849),with sensitivity of 81.56% and specificity of 83.24%,and those values for using Tau protein to predict poor prognosis were 0.847(95%CI=0.764-0.831),82.26%,and 79.68%,respectively,all at high levels. Patients with serum MIF level <64.43 ng/L had significantly better survival than those with serum MIF level ≥ 64.43 ng/L(P<0.05 by log-rank test). Patients with serum Tau protein level<216.25 pg/ml had significantly better survival than those with serum Tau protein level ≥216.25 pg/ml(P<0.05 by log-rank test). Conclusion Patients with severe HICH had significantly higher serum MIF and Tau protein levels than healthy people. The patients with poor prognosis had significantly higher serum MIF and Tau protein levels than those with good prognosis. Serum MIF and Tau protein levels were closely related to the clinical outcome of the patients,which can be used as effective indicators to predict the prognosis of patients with HICH.